Companies / KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals Inc
KALVCIK 1348911FRAMINGHAM, MA
Financials · FY2025
Ownership
53.2M shares outstanding · as of May 7, 2026
Ownership
| 10%+ / strategic | 19.81% | 10,547,461 |
| Institutions | 117.72% | 62,676,795 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 20
View all →| Insider | % of shares | Shares |
|---|---|---|
| 9.56% | 5,089,354 | |
Audhya Paul K.CHIEF MEDICAL OFFICER | 0.00% | 0 |
Palleiko Benjamin LCEOCHIEF EXECUTIVE OFFICER · Director | 0.00% | 0 |
Piekos BrianChief Financial Officer | 0.00% | 0 |
Sweeny NicoleFormerChief Commercial Officer | 0.00% | 0 |
Yea ChristopherFormerCHIEF DEVELOPMENT OFFICER | 0.00% | 0 |
Arif BilalFormerChief Operations Officer | — | — |
Fairey WilliamDirector | — | — |
Koh Bong Y10% owner | — | — |
Pereira Brian JGDirector | — | — |
Institutional holders 168
View all →| Holder | Value | % of shares |
|---|---|---|
| $108.67M | 12.64% | |
| $92.07M | 8.59% | |
| $81.39M | 9.47% | |
| $77.01M | 8.96% | |
| $60.63M | 7.05% | |
| $45.36M | 5.28% | |
| $40.52M | 4.71% | |
| $39.20M | 4.56% | |
| $38.49M | 3.59% | |
| $36.88M | 4.29% |
Activity
Mar 31, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Exit | — | $-60.63M | -3.8M -100.00% | — | high |
| Q2 2026 as of | State Street Corporation 13F manager | Exit | — | $-30.87M | -1.9M -100.00% | — | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Trim | — | $-19.82M | -985K -33.99% | 1,912,146 3.59% of shares | medium |
| Q1 2026 as of | Schroder Investment Management Group 13F manager | Trim | — | $-12.21M | -665K -56.75% | 506,743 0.95% of shares | medium |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Trim | — | $-5.80M | -288K -75.31% | 94,400 0.18% of shares | medium |
| Q3 2025 as of | Barclays PLC 13F manager | Add | — | $4.98M | +409K +242.11% | 577,904 1.09% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | New | — | $3.28M | +163K | 162,908 0.31% of shares | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | New | — | $3.09M | +153K | 153,459 0.29% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Point72 Asset Management, L.P. | Passive13G/A | — |
| Point72 Asset Management, L.P. | Passive13G | — |
| Glazer Capital, LLC | Passive13G | — |
| Millennium Management LLC | Passive13G/A | — |
| Point72 Asset Management, L.P. | Passive13G/A | — |
| SilverArc Capital Management, LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| KALV | — | 483497103 |